This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Preclinical Animal Pharmacokinetics (PK) Study
Introduction
Are you facing bottlenecks in candidate selection or struggling with complex data integration in early-phase drug metabolism? At BioVenic, we offer non-GLP Preclinical Animal PK Studies in rodents and non-rodents. We use strong in vivo models with various bioanalytical platforms to provide high-quality ADME data, making your preclinical work easier and enabling fast, informed decisions.
Our Services
In Vitro ADME and Physicochemical Analysis
BioVenic offers in vitro profiling for early-stage compound optimization. Our scientists use validated tests to assess permeability, solubility, and metabolic stability, helping you choose candidates with good drug-like properties.
Focus of Study: To find issues in absorption and metabolism before moving to costly in vivo stages.
| Category | Key Experimental Items | Research Focus |
|---|---|---|
| Physicochemical | Kinetic/Thermodynamic Solubility, logP/logD, pKa | Baseline profiling for formulation and bioavailability. |
| Absorption | Caco-2 Permeability, PAMPA, Transporter Substrate Assays | Predicting intestinal absorption and efflux potential. |
| Distribution | Plasma Protein Binding (PPB), Blood-to-Plasma Ratio | Determining the free fraction of drug available for action. |
| Metabolism | Liver Microsome/Hepatocyte Stability, CYP Inhibition/Induction | Identifying metabolic clearance pathways and DDI risks. |
In Vivo Pharmacokinetics: Model Selection
BioVenic offers a diverse range of animal models to characterize systemic exposure and disposition. We focus on cross-species scaling to provide a holistic view of your compound's behavior.
Rodent Models (Mice & Rats): Used in early PK screening for dose-range finding and high-throughput lead optimization.
Non-Rodent Models (Dogs & Rabbits): Used for larger blood volume needs and special delivery methods like dermal or oral long-term monitoring.
Non-Human Primates: Used for high-level cross-species comparison when metabolic enzymes are similar to or specific to primates.
Sample Collection and Bioanalytical Excellence
BioVenic customizes sampling to capture the full kinetic profile, from absorption to elimination, so no important data is missed.
Collected Matrices: Whole blood, plasma, serum, urine, feces, and key tissues like liver, kidney, lung, heart, and brain.
Bioanalytical Technologies:
LC-MS/MS: For high-sensitivity quantification of small molecules and metabolites.
HPLC-UV/FLD: For analyzing high-concentration compounds.
Immunoassays (ELISA): For detecting peptides and large molecules.
BioVenic Preclinical Animal Pharmacokinetics (PK) Service Workflow
Applications of BioVenic Preclinical Animal Pharmacokinetics (PK) Study
BioVenic PK services are suitable for a wide range of modalities, including:
- Small Molecule Compounds (Chemical entities)
- Peptides and Proteins
- Antibodies and Large Molecules
- Nucleic Acid-based Modalities
- Novel Delivery Systems (Liposomes and Nanoparticles)
Advantages of BioVenic Preclinical Animal Pharmacokinetics (PK) Study
Diverse Model Library
Access a wide range of validated models with the capability to develop customized protocols tailored to unique delivery strategies.
Robust Detection Platforms
BioVenic's multi-matrix testing platform handles complex tissue homogenates and biological fluids with high precision.
One-Stop Integration
BioVenic offers a seamless transition from in vitro screening to in vivo PK, consolidating your research needs under one roof to save time and reduce variability.
What You Get: Preclinical PK & ADME Deliverables
To keep your drug development program milestone-driven and decision-ready, BioVenic provides clear, high-quality data packages across every stage of the ADME/PK workflow.
Stage 1: In Vitro ADME & Physicochemical Profiling
Outputs:
- Physicochemical Baseline: Comprehensive data on solubility (Kinetic/Thermodynamic), lipophilicity (logP/logD), and pKa for formulation optimization.
- Permeability & Absorption Report: Caco-2, PAMPA, and Transporter Substrate Assay results to predict intestinal absorption and efflux potential.
- Metabolic & Distribution Summary: Liver microsome/hepatocyte stability profiles, CYP inhibition/induction data, and Plasma Protein Binding (PPB) fractions to identify DDI risks and free drug availability.
Stage 2: In Vivo PK Study Design & Execution
Deliverables:
- Model Selection Strategy: A tailored study plan utilizing Rodent (Mouse/Rat), Non-Rodent (Dog/Rabbit), or Non-Human Primate models based on your cross-species scaling needs.
- Customized Sampling Protocol: Defined schedules for capturing full kinetic profiles across multiple matrices, including whole blood, plasma, serum, urine, feces, and key tissues (Liver, Kidney, Lung, Heart, Brain).
- Dose-Range Finding (DRF) Results: Initial systemic exposure data to guide high-throughput lead optimization.
Stage 3: Bioanalytical Excellence & Quantification
Outputs:
- High-Sensitivity Data: Quantification of small molecules and metabolites via LC-MS/MS or HPLC-UV/FLD for high-concentration compounds.
- Large Molecule Analysis: Validated Immunoassay (ELISA) results for peptides and recombinant proteins.
- Validated Method Summary: Brief overview of the analytical methods and equipment used to ensure data integrity and sensitivity.
Stage 4: Comprehensive PK Data Package
Deliverables:
- Raw & Processed Kinetic Data: Final concentration-time curves and raw data tables for all tested matrices.
- Non-Compartmental Analysis (NCA): Key PK parameters including Cmax, Tmax, t1/2, AUC, Clearance (Cl), and Volume of Distribution (Vd).
- Bioavailability (F%) & Cross-Species Comparison: Assessment of systemic exposure and disposition to support decisions and human dose prediction.
Case Study: Preclinical Pharmacokinetic Evaluation
BioVenic provides a preclinical pharmacokinetic (PK) service optimized for evaluating the targeting efficiency and metabolic profiles of novel therapies. We offer rigorous in vivo distribution analysis using tumor-bearing models, quantifying ligand localization through sequential ex vivo biodistribution studies to map activity across multiple time points. By measuring the percentage of injected activity per gram of tissue (%IA/g), we utilize non-compartmental analysis (NCA) to calculate the area under the curve (AUC), delivering precise determinations of residence times and clearance rates within both tumors and organs-at-risk. By providing high-resolution data on therapeutic indices and nephrotoxicity risks, we deliver the robust evidence necessary to identify superior candidates for targeted cancer treatment and accelerate their transition toward future applications.
Fig. 1 Time-dependent distribution of [177Lu]Lu-DOTA-MGS5 in A431-CCK2R xenografted BALB/c nude mice1
FAQs
What R&D challenges can your PK services help solve?
BioVenic's PK services tackle key drug development milestones. We determine systemic exposure by providing concentration-time profiles and key parameters like Cmax and AUC to help set First-in-Human doses. We evaluate absorption by checking oral bioavailability and first-pass effects while studying different administration routes such as PO, IV, SC, and Inhalation. We elucidate distribution and tissue penetration by measuring plasma protein binding, blood-brain barrier permeability, and distribution in target tissues like the liver, kidney, lung, and tumors. We reveal metabolism and elimination by identifying metabolic rates, characterizing metabolites, and determining renal versus biliary excretion. Our services support Drug-Drug Interaction (DDI) assessments through CYP/UGT tests and transporter interactions. Lastly, we provide baselines for PK/PD modeling by combining PK data with efficacy results to create dose-response models for dose escalation and safety evaluations.
Which animal models does your company utilize, and how should I choose the right one?
Model selection depends on your study objectives, metabolic similarity, and delivery route:
Mice / Rats: The most cost-effective options with high throughput. They are ideal for early-stage concentration-time curve exploration and metabolic enzyme phenotype screening.
Beagle Dogs / Rabbits: Provide enough blood for intensive sampling, suitable for determining oral bioavailability and plasma protein binding.
Pigs: Similar GI structures and skin thickness to humans, used for absorption studies with transdermal, inhalation, or special delivery methods.
Cynomolgus / Rhesus Macaques: Have metabolic enzymes, plasma proteins, and BBB characteristics most like humans, preferred for PK/PD correlation, DDI validation, and bioequivalence studies.
How do you handle samples that require special stability conditions?
We utilize cold-chain processing, stabilized anticoagulants, and immediate flash-freezing to preserve sample integrity.
Contact Us
From early in vitro screening to definitive in vivo PK profiles, BioVenic's team of expert scientists is dedicated to providing the high-quality data you need for successful candidate advancement. We offer flexible, non-GLP preclinical solutions that connect discovery and development. Contact us to discuss your project needs and receive a custom quote.
Reference
- Zavvar, Taraneh Sadat et al. "Radiopharmaceutical formulation and preliminary clinical dosimetry of [177Lu]Lu-DOTA-MGS5 for application in peptide receptor radionuclide therapy." European journal of nuclear medicine and molecular imaging vol. 52,4 (2025): 1321-1331. https://doi.org/10.1007/s00259-024-06979-1. Distributed under Open Access license CC BY 4.0. The original title was changed to "Time-dependent distribution of [177Lu]Lu-DOTA-MGS5 in A431-CCK2R xenografted BALB/c nude mice".